The Hippo Signaling Pathway and Cancer

Dr. Moshe Oren has been investigating the molecular biology of cancer-related processes for years, with particular emphasis on the p53 tumor suppressor and its associated network of proteins and genes. Dr. Oren has cloned he p53 gene when he was a post doc working under Dr. Arnold Levine. He has acted as a member of several international research consortia, as well as co-organizer of numberous national and international conferences. Dr. Oren has won several cancer research awards and his most recent achievement includes serving as President Elect of the European Association for Cancer Research in 2010. He serves on several editorial boards including Molecular Cell, EMBO Journal, Molecular and Cellular Biology, Molecular Carcinogenesis, and Molecular Oncology, to name a few. Dr. Yael Aylon is a research associate in Dr. Oren's lab at the Weizmann Institute and has been invited to speak at several international conferences and seminar.

​​​​​Introduction.- Merlin and Angiomotin in Hippo-Yap signaling.- MST1/2 and other upstream signaling that affect Hippo pathway function.- YAP1 uses its modular protein domains and conserved sequence motifs to orchestrate diverse repertoires of signaling.- Regulation of YAP and TAZ transcription co-activators.- Regulation of YAP and TAZ by epithelial plasticity.- Hippo pathway and apoptosis.- YAP and p73: a matter of mutual specificity in tumour suppression.- The c-Abl/YAP/p73 apoptotic module and the Hippo pathway.- Hippo in cell cycle and mitosis.- Hippo and mouse models for cancer.- Roles of Hippo signaling during mouse embryogenesis.- Hippo Signaling and stem cells.- Hippo signaling and organ size control.- Hippo signaling in heart development.- Cell competition and the Hippo pathway.- Non-canonical roles from the Hippo pathway.- Index.